Venetoclax
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Explore 34 assets in High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit →Floatz Rating
B58/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06649812CT.gov Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | — | Recruiting | — | — | — |
NCT04285268CT.gov Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | — | Withdrawn | — | — | — |
NCT01742988CT.gov Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Venetoclax (this asset) | National Cancer Institute (NCI) | P2 | B · 58 |
| Rituximab | Yazeed Sawalha | P2 | B |
| Cyclophosphamide | Mayo Clinic | P2 | B |
| (+)-Vincristine | Patrick C. Johnson, MD | P2 | B |
| Dexasone | National Cancer Institute (NCI) | P2 | B |
| Ibrutinib | National Cancer Institute (NCI) | P2 | B |
| Etoposide | David Bond, MD | P2 | B |
| Prednisone | National Cancer Institute (NCI) | P2 | B |
| Pegfilgrastim | M.D. Anderson Cancer Center | P2 | CCC |
+32 more in the High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit cohort
Other indications for Venetoclax
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P4 | BB · 70 |
| Acute Myeloid Leukemia | — | P4 | BB · 69 |
| Chronic Myelomonocytic Leukemia | — | P2/3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Venetoclax in High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/venetoclax-high-grade-b-cell-lymphoma-double-hittriple-hit
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →